52.14
4.16%
2.08
시간 외 거래:
52.55
0.41
+0.79%
전일 마감가:
$50.06
열려 있는:
$50
하루 거래량:
1.23M
Relative Volume:
1.48
시가총액:
$5.24B
수익:
$523.53M
순이익/손실:
$118.02M
주가수익비율:
64.37
EPS:
0.81
순현금흐름:
$124.84M
1주 성능:
+8.15%
1개월 성능:
+14.77%
6개월 성능:
+112.64%
1년 성능:
+103.51%
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
149 COMMONWEALTH DRIVE, MENLO PARK
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-11-06 | 업그레이드 | Truist | Hold → Buy |
2023-04-11 | 개시 | SVB Securities | Market Perform |
2023-04-04 | 개시 | Piper Sandler | Overweight |
2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
2022-06-27 | 재개 | Canaccord Genuity | Buy |
2022-02-02 | 개시 | Canaccord Genuity | Buy |
2022-01-28 | 개시 | Truist | Buy |
2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
2019-09-24 | 개시 | Jefferies | Buy |
2019-09-06 | 개시 | H.C. Wainwright | Buy |
2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
2018-08-10 | 재확인 | Stifel | Hold |
2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
2017-08-31 | 개시 | Stifel | Buy |
2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
2015-04-21 | 개시 | FBR Capital | Outperform |
2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Here is Why Growth Investors Should Buy Corcept (CORT) Now - Yahoo Finance
Corcept (CORT) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance Australia
Corcept Stock At New High; Will The Upcoming Regulatory And Clinical Trial Catalysts Take It Higher? - RTTNews
Roman Butler Fullerton & Co. Sells 10,466 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Creative Planning Acquires 841 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics (NASDAQ:CORT) Reaches New 1-Year HighStill a Buy? - MarketBeat
Corcept Therapeutics stock soars to all-time high of $50.23 By Investing.com - Investing.com Australia
Corcept Therapeutics stock soars to all-time high of $50.23 - Investing.com
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade - Yahoo Canada Finance
Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why - Yahoo Canada Finance
What is HC Wainwright’s Forecast for CORT FY2024 Earnings? - Defense World
Research Analysts Issue Forecasts for CORT FY2024 Earnings - MarketBeat
What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View - MSN
Corcept Therapeutics (CORT) Stock Declines Amid Market Activity - GuruFocus.com
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy? - MSN
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.2%Here's What Happened - MarketBeat
FY2026 Earnings Estimate for CORT Issued By HC Wainwright - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2024 Earnings Call Transcript - Insider Monkey
Corcept’s relacorilant GRADIENT trial misses primary endpoint - Yahoo Finance
Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Corcept Therapeutics reports robust Q3 growth, raises guidance - Investing.com Canada
Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Expansion - GuruFocus.com
Corcept Therapeutics Inc (CORT) Q3 2024 Earnings: EPS of $0.41 B - GuruFocus.com
HC Wainwright Reiterates Buy Rating for Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates - MSN
Corcept: Q3 Earnings Snapshot - Milford Mirror
Corcept reports robust revenue growth in Q3 By Investing.com - Investing.com Canada
abrdn plc Purchases 142,310 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update - StockTitan
Earnings Preview: Corcept Therapeutics - Benzinga
Boston Trust Walden Corp Sells 69,924 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (CORT) Set to Announce Earnings on Wednesday - MarketBeat
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Yahoo Finance
Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength? - MSN
Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise - Yahoo Finance
Corcept stock stays a buy, with analyst eyeing validation of relacorilant’s cancer-fighting mechanism - Investing.com UK
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) PT at $65.25 - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Position Reduced by Exchange Traded Concepts LLC - Defense World
Exchange Traded Concepts LLC Decreases Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Corcept Therapeutics (CORT) Stock Jumps Over 5% Amid Solid Finan - GuruFocus.com
HC Wainwright Increases Corcept Therapeutics (NASDAQ:CORT) Price Target to $80.00 - MarketBeat
Corcept Therapeutics stock target raised, buy rating on Cushing's franchise growth - Investing.com Canada
Key Takeaways From Corcept Therapeutics Analyst Ratings - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Sets New 12-Month HighHere's Why - MarketBeat
Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High? - Yahoo Finance
Corcept Therapeutics stock hits all-time high at $47.81 - Investing.com
Corcept Therapeutics stock hits all-time high at $47.81 By Investing.com - Investing.com UK
Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):